Neurocrine to acquire Diurnal Group for £48.3M cash

NEUROCRINE BIOSCIENCES INC

Acquiring entire issued share capital of Diurnal for ~£48.3M (~$56.5M) in an all-cash transaction.
Transaction conditional on approval by Diurnal shareholders and other customary closing conditions.
Neurocrine expects deal to accelerate establishment of UK clinical development and commercial capabilities.
Announcement made under Rule 2.7 of the UK City Code on Takeovers and Mergers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.